Automate Your Wheel Strategy on ASMB
With Tiblio's Option Bot, you can configure your own wheel strategy including ASMB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ASMB
- Rev/Share 3.0288
- Book/Share 3.6147
- PB 3.9008
- Debt/Equity 0.1113
- CurrentRatio 2.0486
- ROIC -0.8505
- MktCap 107689455.0
- FreeCF/Share -7.4878
- PFCF -1.916
- PE -2.6514
- Debt/Assets 0.0305
- DivYield 0
- ROE -1.3177
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ASMB | Guggenheim | -- | Buy | -- | $31 | March 25, 2025 |
| Upgrade | ASMB | Jefferies | Hold | Buy | $2 | $35 | Sept. 20, 2024 |
News
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1a trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis delta virus (HDV) entry inhibitor candidate.
Read More
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose –
Read More
About Assembly Biosciences, Inc. (ASMB)
- IPO Date 2010-12-17
- Website https://www.assemblybio.com
- Industry Biotechnology
- CEO Mr. Jason A. Okazaki J.D.
- Employees 73